Abstract: The invention provides a data base of LDL, I, IIa, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HDl quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment.

Abstract: The invention provides a method (e.g., a computer algorithm) for calculating a number of particles in a HDL subfraction. The method features the steps of: 1) measuring an initial distribution of HDL particles (e.g., a relative mass distribution) from a blood sample; 2) processing the initial distribution of HDL particles with a mathematical model to determine a modified distribution of HDL particles (e.g., a relative particle distribution); 3) determining a total apo-AI content value from a blood sample; and 4) analyzing both the modified distribution of particles and the total apo-AI content value to calculate the apo-AI content value in an HDL subfraction.

Abstract: This invention is directed to a data base which contains data for HDL2b, LDL IIIa & LDL IIIb and LDL IVb subclasses all in mg/Dl and which is correlated to cardiovascular disease.

Abstract: The invention provides a method (e.g., a computer algorithm) for calculating a number of particles in a LDL subfraction. The method features the steps of: 1) measuring an initial distribution of LDL particles (e.g., a relative mass distribution) from a blood sample; 2) processing the initial distribution of LDL particles with a mathematical model to determine a modified distribution of LDL particles (e.g., a relative particle distribution); 3) determining a total LDL particle number value from a blood sample; and 4) analyzing both the modified distribution of particles and the total LDL particle number value to calculate the particle number value in an LDL subfraction.

Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III a+b and HDL 2b are preferred subclasses.

Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels.

Abstract: The invention provides a data base of LDL, I, Ia, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HD1 quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment.

Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels.